Giorgio Bolis

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

W ten Bokkel Huinink, Martin Gore, J Carmichael et al. · Journal of Clinical Oncology · 1997 · 681 citations

A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery

Giancarlo Agnelli, Giorgio Bolis, Lorenzo Capussotti et al. · Annals of Surgery · 2005 · 680 citations · Full text

Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial

J. Baptist Trimbos, Ignace Vergote, Giorgio Bolis et al. · JNCI Journal of the National Cancer Institute · 2003 · 679 citations · Full text

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

G.J. Creemers, Giorgio Bolis, M. Gore et al. · Journal of Clinical Oncology · 1996 · 386 citations

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

M. A. Bookman, Henric Malmström, Giorgio Bolis et al. · Journal of Clinical Oncology · 1998 · 334 citations